BioLife Solutions (NASDAQ:BLFS) Price Target Raised to $33.00 at KeyCorp

BioLife Solutions (NASDAQ:BLFS) had its target price increased by KeyCorp from $30.00 to $33.00 in a research note published on Friday,Benzinga reports. The firm currently has an overweight rating on the medical equipment provider’s stock.

A number of other research firms also recently commented on BLFS. Craig Hallum lifted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $28.29.

BioLife Solutions Price Performance

Shares of BLFS opened at $26.70 on Friday. BioLife Solutions has a 52 week low of $13.99 and a 52 week high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -25.19 and a beta of 1.91. The stock has a 50 day moving average of $24.62 and a 200-day moving average of $23.55.

Insider Activity at BioLife Solutions

In related news, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. This trade represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,313 shares of company stock worth $1,572,899 in the last ninety days. 2.20% of the stock is owned by insiders.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently bought and sold shares of the stock. Fred Alger Management LLC increased its position in shares of BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares during the period. State Street Corp lifted its holdings in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares during the period. Geode Capital Management LLC boosted its stake in BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after acquiring an additional 66,422 shares during the period. Finally, Rockefeller Capital Management L.P. raised its position in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after acquiring an additional 262,504 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.